目录产品 » CS1/CRACC/SLAMF7, His & Avi, Human
Manual
SDS
COAs

CS1/CRACC/SLAMF7, His & Avi, Human

CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family, a self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune responses.
￥1600
Z03649-100

产品简介
Species Human
Protein Construction
SLAMF7 (Ser23-Met226)
Accession # Q9NQ25		 Poly-His Avi
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Endotoxin Level ≤ 1 EU/μg of protein by LAL method
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized CS1/CRACC/SLAMF7, His & Avi, Human at 1μg/ml (100μl/well) on the plate can bind Anti­SLAMF7 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 25.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

图例
CS1/CRACC/SLAMF7, His & Avi, Human

Immobilized SLAMF7, His & Avi tag at 1 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA. »

CS1/CRACC/SLAMF7, His & Avi, Human

Recombinant Human CRACC/SLAMF7 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%. »

CS1/CRACC/SLAMF7, His & Avi, Human

The purity of Recombinant Human CRACC/SLAMF7 Protein is greater than 95% as determined by SEC-HPLC. »

CS1/CRACC/SLAMF7, His & Avi, Human

Immobilized CS1/CRACC/SLAMF7, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 2.2 ng/ml determined by ELISA. »

CS1/CRACC/SLAMF7, His & Avi, Human

The purity of CS1/CRACC/SLAMF7, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »

CS1/CRACC/SLAMF7, His & Avi, Human

CS1/CRACC/SLAMF7, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

技术背景
Target Background CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family, a self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune responses.
Synonyms CD319 antigen; CD319; 19A; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CRACC; CRACCCD2-like receptor-activating cytotoxic cells; CS119A24 protein; Membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; Novel Ly9; Protein 19A; SLAM family member 7; SLAMF7; CS1
返回

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.